Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.77 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.60 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531716 | 0.98 | POLB (0.74) | POLBNCOA1NCOA3CYP1A2TSHR | |
| Quinoline SCHEMBL28245218 | 0.90 | POLB (0.73) | POLBNCOA1NCOA3CYP1A2TSHR | |
| SCHEMBL29611471 | 0.87 | POLB (1.00) | POLBNCOA1NCOA3CYP1A2TSHR | |
| SCHEMBL29750649 | 0.87 | POLB (1.00) | POLBNCOA1NCOA3CYP1A2TSHR | |
| SCHEMBL827685 | 0.87 | POLB (1.00) | POLBNCOA1NCOA3CYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL7950313 | 0.85 | POLB (0.96) | POLBNCOA1NCOA3CYP1A2TSHR | |
| Quinoline SCHEMBL9110913 | 0.83 | POLB (0.84) | POLBNCOA1NCOA3CYP1A2TSHR | |
| SCHEMBL8924368 | 0.83 | POLB (0.55) | POLBNCOA1NCOA3CYP1A2TSHR | |
| SCHEMBL11766903 | 0.80 | NCOA1 (0.68) | POLBNCOA1NCOA3CYP1A2TSHR | |
| Selenium SCHEMBL10543234 | 0.80 | POLB (0.84) | POLBNCOA1NCOA3CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120032751-A | Method for obtaining effect trigger value of in-vitro genotoxicity test of water environment sample and application thereof | 中国科学院生态环境研究中心 | 2025-05-23 | — | — | CN | claimed |
| EP-4496889-A1 | METHOD FOR DETECTING THE MUTAGENIC CHARACTER OF CHEMICAL COMPOUNDS | Genevolution (FR) | 2025-01-29 | — | — | EP | claimed |
| WO-2023180209-A1 | METHOD FOR DETECTING THE MUTAGENIC CHARACTER OF CHEMICAL COMPOUNDS | GENEVOLUTION (FR) | 2023-09-28 | — | — | WO | claimed |
| EP-3199630-B1 | CONTINUOUS DIRECTED EVOLUTION OF PROTEINS AND NUCLEIC ACIDS | HARVARD COLLEGE (US) | 2019-05-08 | — | — | EP | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| EP-2904406-B1 | METHOD FOR MEASURING ATR INHIBITION MEDIATED INCREASES IN DNA DAMAGE | VERTEX PHARMA (US) | 2018-03-21 | — | — | EP | claimed |
| US-20170298444-A1 | METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-19 | — | — | US | claimed |
| US-9791456-B2 | Method for measuring ATR inhibition mediated increases in DNA damage | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-10-17 | — | — | US | claimed |
| EP-3198277-A1 | METHODS FOR PREDICTING THE RISK OF DEVELOPING BREAST CANCER | Dana Farber Cancer Institute, Inc. (US) | 2017-08-02 | — | — | EP | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| EP-2904406-A1 | METHOD FOR MEASURING ATR INHIBITION MEDIATED INCREASES IN DNA DAMAGE | Vertex Pharmaceuticals Incorporated (US) | 2015-08-12 | — | — | EP | claimed |
| US-8999632-B2 | Method for measuring ATR inhibition mediated increases in DNA damage | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-07 | — | — | US | claimed |
| US-20140134596-A1 | Method for Measuring ATR Inhibition mediated increases in DNA damage | VERTEX PHARMACEUTICALS INCORPORATED | 2014-05-15 | — | — | US | claimed |
| WO-2014055756-A1 | METHOD FOR MEASURING ATR INHIBITION MEDIATED INCREASES IN DNA DAMAGE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-10 | — | — | WO | claimed |
| EP-1921157-B1 | Processes for detecting toxic substances | DAIKIN IND LTD (JP) | 2010-05-26 | — | — | EP | claimed |
| EP-1045899-A2 | METHOD OF DETERMINING THE FUNCTION OF NUCLEOTIDE SEQUENCES AND THE PROTEINS THEY ENCODE BY TRANSFECTING THE SAME INTO A HOST | Biosource Technologies, Inc. (US) | 2000-10-25 | — | — | EP | claimed |
| WO-1999036516-A2 | METHOD OF DETERMINING THE FUNCTION OF NUCLEOTIDE SEQUENCES AND THE PROTEINS THEY ENCODE BY TRANSFECTING THE SAME INTO A HOST | BIOSOURCE TECHNOLOGIES, INC. (US) | 1999-07-22 | — | — | WO | claimed |
| EP-0397474-B1 | Photosensitive composition | TOSHIBA KK (JP) | 1997-12-10 | — | — | EP | claimed |
| EP-0576622-B1 | LITHOGRAPHIC PRINTING PLATES | EASTMAN KODAK CO (US) | 1997-11-05 | — | — | EP | claimed |
| EP-0543307-A2 | Nootropic agent | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-05-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | POLB 1829/4885NCOA1 2446/4885NCOA3 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.